RegeneRx Biopharmaceuticals, Inc. filed its 10-K on Mar 30, 2022 for the period ending Dec 31, 2021. In this report its auditor, CohnReznick LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0014 USD | 0.00% | 0.00% | +16.67% |
1st Jan change | Capi. | |
---|---|---|
+16.67% | 2.11K | |
+0.10% | 91.42B | |
+2.76% | 41.08B | |
-9.06% | 34.26B | |
+54.63% | 25.27B | |
-16.61% | 15.27B | |
-9.14% | 12.81B | |
-12.11% | 11.6B | |
-43.61% | 11.42B | |
+5.39% | 9.16B |
- Stock Market
- Equities
- RGRX Stock
- News RegeneRx Biopharmaceuticals, Inc.
- RegeneRx Biopharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt